Wall Street analyst price targets, ratings consensus & upside potential · Updated Feb 28, 2026
Last 12 months price action with 12-month analyst target path
As of February 28, 2026, Mineralys Therapeutics, Inc. (MLYS) has a Wall Street consensus price target of $52.00, based on estimates from 8 covering analysts. With the stock currently trading at $29.26, this represents a potential upside of +77.7%. The company has a market capitalization of $2.31B.
Analyst price targets range from a low of $52.00 to a high of $52.00, representing a 0% spread in expectations. The median target of $52.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 7 analysts rating the stock as a Buy or Strong Buy,1 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, MLYS trades at a trailing P/E of -8.0x. Analysts expect EPS to grow +9.6% over the next year.
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how MLYS stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonThe consensus Wall Street price target for MLYS is $52, representing 77.7% upside from the current price of $29.26. With 8 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
MLYS has a consensus rating of "Buy" based on 8 Wall Street analysts. The rating breakdown is predominantly bullish, with 7 Buy/Strong Buy ratings. The consensus 12-month price target of $52 implies 77.7% upside from current levels.
MLYS's current price is $29.26 with a consensus target of $52 (77.7% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $52 for MLYS, while the most conservative target is $52. The consensus of $52 represents the median expectation. These targets typically reflect 12-month expectations.
MLYS is moderately covered, with 8 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 7 have Buy ratings, 1 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month MLYS stock forecast based on 8 Wall Street analysts shows a consensus price target of $52, with estimates ranging from $52 (bear case) to $52 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on MLYS, with a "Buy" consensus rating and $52 price target (77.7% upside). 7 of 8 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
MLYS analyst price targets range from $52 to $52, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $52 consensus represents the middle ground.